RxDoctor Payments Data

Xiomara Ramirez-Ortega, MD

Internal Medicine · Clearwater, FLNPI 1619929528

Payments from drug & device makers

$1,404in general payments, 2019–2025

Across 54 payments — averaging $26.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$355
  • Novo Nordisk$127
  • Idorsia Pharmaceuticals US Inc$125
  • Johnson & Johnson$125
  • Pfizer$79
  • AstraZeneca$72
  • plus $521 from 12 others

What the payments were for

  • Food & beverage$1,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$203,387
Medicare patients
284
Services billed
3,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$85,324
OzempicSemaglutide61$68,977
ProliaDenosumab32$55,043
MounjaroTirzepatide27$29,051
TrulicityDulaglutide20$27,044
XareltoRivaroxaban23$19,582
Repatha SyringeEvolocumab13$6,742
Rosuvastatin Calcium554$6,418
Levothyroxine Sodium359$3,659
Atorvastatin Calcium329$2,770
Amlodipine Besylate347$1,786
SynthroidLevothyroxine Sodium28$1,759
Losartan Potassium195$1,756
Pravastatin Sodium137$1,687
Lisinopril221$1,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$127$68,97761 claims
Lilly USA, LLCMounjaro, Trulicity$61$56,09547 claims
AmgenProlia$355$55,04332 claims
Johnson & JohnsonXarelto$125$19,58223 claims
AbbVieSynthroid$54$1,75928 claims
Almatica Pharma LLCSertraline Hcl$18$66994 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →